Daunorubicin citrate

Modify Date: 2024-01-31 18:54:10

Daunorubicin citrate structure	Common Name	Daunorubicin citrate
	CAS Number	1884557-85-0	Molecular Weight	719.64
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₃H₃₇NO₁₇	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Daunorubicin citrate

Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].

Name	Daunorubicin citrate

Description	Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Research Areas >> Infection Signaling Pathways >> Cell Cycle/DNA Damage >> DNA/RNA Synthesis Signaling Pathways >> Antibody-drug Conjugate >> ADC Cytotoxin Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Neurological Disease Signaling Pathways >> Anti-infection >> Bacterial
Target	Topoisomerase II Daunorubicins/Doxorubicins
In Vitro	Daunorubicin citrate (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2]. Daunorubicin citrate (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4]. Daunorubicin citrate (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4]. Daunorubicin citrate (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4]. Daunorubicin citrate (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6]. Cell Viability Assay[3][4] Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line) Concentration: 7 nM-1.9 μM Incubation Time: 72 h Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6). Apoptosis Analysis[4] Cell Line: L3.6 cells Concentration: 0.4 μM Incubation Time: 24 h, 48 h Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h. Western Blot Analysis[6] Cell Line: K562 cells Concentration: 2 μM Incubation Time: 24 h Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.
In Vivo	Daunorubicin citrate (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats[5]. Daunorubicin citrate (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7]. Animal Model: Male Sprague-Dawley rats[5] Dosage: 3 mg/kg Administration: Intravenous injection, three times at 48 h intervals. Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity. Increased urinary protein excretion, serum creatinine, and BUN level.
References	[1]. Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. [2]. Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14. [3]. Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4. [4]. Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26. h [5]. Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9. [6]. Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. [7]. Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013.

Molecular Formula	C₃₃H₃₇NO₁₇
Molecular Weight	719.64

Daunorubicin citrate

Use of Daunorubicin citrate

Names

Daunorubicin citrate Biological Activity

Chemical & Physical Properties